Monthly disclosure of the exercise status of stock acquisition rights. The target month is October 2026, with 1,410,000 shares exercised, 14,100 stock acquisition rights exercised, more than 50,000 shares remaining unexercised, and total outstanding shares of 43,399,118 shares. The exercise restriction ratio is 3.25%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4893","jir_company_name":"Noile-Immune Biotech Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4893-20261102-01.pdf","jir_short_summary":"Monthly disclosure of the exercise status of stock acquisition rights. The target month is October 2026, with 1,410,000 shares exercised, 14,100 stock acquisition rights exercised, more than 50,000 shares remaining unexercised, and total outstanding shares of 43,399,118 shares. The exercise restriction ratio is 3.25%.","jir_summary":"### IR Highlights\nNoile-Immune Biotech Inc. announced the monthly exercise status for stock acquisition rights with an exercise price adjustment clause issued in October 2026. During the period, the number of shares actually exercised was 1,410,000 shares, the total number of stock acquisition rights exercised was 14,100 rights, and the average exercise price of the exercised shares was not disclosed. Unexercised stock acquisition rights total 85,900 rights, and the exercise restriction ratio at the end of the previous month was 3.25%.\n\n### Impact on Shareholders and Outlook\nThis disclosure is a routine follow-up on the exercise status of stock acquisition rights and is viewed as having a limited immediate direct impact on capital structure or dilution. Compliance with exercise restrictions is being managed appropriately, and depending on future exercise activity there is potential to affect the number of outstanding shares.","jir_financial_highlights":"Number of shares delivered in the target month: 1,410,000 shares (Unknown)\nOutstanding shares (as of target month): 43,399,118 shares (Unknown)\nTransferred treasury shares: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NoileImmuneBiotech, #StockAcquisitionRights, #SecuritiesRelated, #ShareIssuance","jir_key_figures":"Number of shares delivered in the target month: 1,410,000 shares\nNumber of unexercised stock acquisition rights: 85,900 rights\nOutstanding shares (as of target month): 43,399,118 shares","jir_meta_title":"Noile-Immune Biotech Inc. Announces Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Clause","jir_meta_description":"Noile-Immune Biotech Inc. published the exercise status for October 2026: 1,410,000 shares delivered, 14,100 rights exercised, 85,900 rights unexercised, outstanding shares 43,399,118. Exercise restriction ratio 3.25%.","jir_og_title":"Noile-Immune Biotech Inc. Announces Monthly Exercise Status of Stock Acquisition Rights","jir_og_description":"October 2026 exercise status: 1,410,000 shares delivered, 85,900 rights unexercised, outstanding shares 43,399,118, exercise restriction ratio 3.25%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59659,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-140334","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n